Cart
sales@molnova.com
PF-04418948
CAS No. 1078166-57-0
PF-04418948( —— )
Catalog No. M10315 CAS No. 1078166-57-0
PF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 2MG | 38 | In Stock |
|
| 5MG | 60 | In Stock |
|
| 10MG | 86 | In Stock |
|
| 25MG | 186 | In Stock |
|
| 50MG | 315 | In Stock |
|
| 100MG | 348 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF-04418948
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM.
-
DescriptionPF-04418948 (PF 04418948) is a novel potent and selective prostaglandin EP2 receptor antagonist; inhibits prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells with a functional K(B) value of 1.8 nM; attenuates the butaprost-induced cutaneous blood flow response in rats; orally active.(In Vitro):PF-04418948 (2 μM; 90 min) inhibits prostaglandin E2 (PGE2)-induced increase in cAMP.(In Vivo):PF-04418948 (oral gavage; 1, 3, and 10 mg/kg; once) attenuats the butaprost-induced cutaneous blood flow response.
-
In VitroPF-04418948 (2 μM; 90 min) inhibits prostaglandin E2 (PGE2)-induced increase in cAMP. Cell Viability Assay Cell Line:CHO cells Concentration:2 μM Incubation Time:90 min Result:Inhibited prostaglandin E2 (PGE2)-induced increase in cAMP in cells expressing EP2 receptors with a functional KB value of 1.8 nM.
-
In VivoPF-04418948 (oral gavage; 1, 3, and 10 mg/kg; once) attenuats the butaprost-induced cutaneous blood flow response. Animal Model:Sprague Dawley rats Dosage:1, 3, and 10 mg/kg Administration:Oral gavage; 1, 3, and 10 mg/kg; once Result:Reduced the peak and AUC butaprost-induced cutaneous blood flow response in a dose-dependent fashion.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorPGE2
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1078166-57-0
-
Formula Weight409.407
-
Molecular FormulaC23H20FNO5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCOC1=CC2=C(C=C1)C=C(C=C2)OCC3(CN(C3)C(=O)C4=CC=C(C=C4)F)C(=O)O
-
Chemical Name3-Azetidinecarboxylic acid, 1-(4-fluorobenzoyl)-3-[[(6-methoxy-2-naphthalenyl)oxy]methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. af Forselles KJ, et al. Br J Pharmacol. 2011 Dec;164(7):1847-56.
2. Birrell MA, et al. Br J Pharmacol. 2013 Jan;168(1):129-38.
3. Kach J, et al. J Biol Chem. 2014 Mar 14;289(11):7505-13.
molnova catalog
related products
-
Tafluprost
Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.
-
Pirmagrel
pirmagrel is a potent thromboxane synthase inhibitor.
-
BW 245C
BW 245C is a selective prostaglandin-like DP receptor (DP1) agonist, a prostaglandin analogue with inhibitory effects on the aggregation response of collagen, which can be used to study diseases such as stroke.
